News

Ketoacidosis not linked to diabetes in woman with SMA type 2

The case of a woman with spinal muscular atrophy (SMA) type 2 who developed an abnormal accumulation of molecules called ketone bodies was described in a recent case report in the U.S. Called ketoacidosis, this occurs when fats are broken down to obtain energy, resulting in ketone bodies being…

In memoriam, Michael Morale: Aug. 8, 1965-June 7, 2025

It is with deep sadness and heavy hearts that we announce the passing of our beloved friend, coworker, and advocate, Michael Morale. Michael died in his home in Irving, Texas, on June 7 at the age of 59. I first encountered Michael through his personal YouTube channel in 2018.

Evrysdi tablets approved as SMA treatment in Europe

The European Commission (EC) has approved a tablet formulation of spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam). “The new Evrysdi tablet with its flexible administration represents progress toward more versatile SMA disease management,” Levi Garraway, MD, PhD, chief medical officer and head of global product development at Roche,…

School-age SMA children more independent on Spinraza: Study

After Spinraza (nusinersen) treatment for slightly longer than one year, school-aged children with spinal muscular atrophy (SMA) showed improved motor function and more independence in tasks involving their arms and hands, a study from China has found. These motor function improvements were linked to reduced symptoms of anxiety…

Treatment with AJ201 shows positive signs in SBMA clinical trial

Treatment with AJ201 was well tolerated and showed signs of improving physical activity in a clinical trial involving people with spinal and bulbar muscular atrophy (SBMA), according to new data announced by developer Annji Pharmaceutical. “I am greatly encouraged by the positive clinical outcomes observed after a relatively…

SMA gene therapy GC101 found safe, effective in animals

Gene therapy GC101 was found to rescue disease manifestations in a mouse model of spinal muscular atrophy (SMA) type 3 and to be safe in non-human primates, supporting its move into clinical testing. Genecradle Therapeutics is sponsoring ongoing Phase 1/2 clinical trials in SMA type 1 (NCT05824169),…